GlassScriptPhysician profile
Venkata Subhash Gorrepati
NPI 1154633675
$19,748.71
in general payments reported to CMS, 2019-2025
25 companies · $992 in 2025
The $992 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.00 · 2021: $13K · 2022: $1,437 · 2023: $2,085 · 2024: $2,170 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,192 · Travel and Lodging: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,192.17 |
| Travel and Lodging | $2,054.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15,316.20 | 2021-2025 | General - Biliary Devices |
| Abbvie INC. | $1,002.68 | 2023-2025 | |
| Ovesco Endoscopy USA, INC. | $887.72 | 2023 | |
| Olympus Corporation of The Americas | $547.82 | 2022-2023 | Disposable Distal Attachment, Olympus, Single Use Electrosurgical Knife Kd-655 |
| Micro-Tech Endoscopy USA, INC. | $286.32 | 2024 | |
| Janssen Biotech, INC. | $221.19 | 2020-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $150.38 | 2023-2025 | Omvoh |
| Apollo Endosurgery US INC | $145.20 | 2023 | Orbera Intragastric Balloon System |
| Madrigal Pharmaceuticals | $135.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $127.08 | 2023-2025 | |
| Gilead Sciences, INC. | $126.68 | 2023-2025 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $125.88 | 2023-2025 | Entyvio, Gattex |
| Celgene Corporation | $106.57 | 2023 | Zeposia |
| Olympus America INC. | $98.21 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.90 | 2023-2024 | Trulance, Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $75.57 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $58.93 | 2023-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $44.45 | 2023-2024 | Dupixent |
| Pfizer INC. | $43.88 | 2023-2025 | |
| Qol Medical, LLC | $41.35 | 2025 | Sucraid |
| Vivus LLC | $31.68 | 2023-2024 | Qsymia |
| Fujifilm Healthcare Americas Corporation | $25.93 | 2022 | |
| Celltrion USA INC. | $24.37 | 2024 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $17.85 | 2025 | Voquezna |
| Amgen INC. | $14.28 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkata Subhash Gorrepati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.